AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2020272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2020272 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 10
Study 7037756 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimipramine
Number of subjects: 41
Study 7037756 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 41
Study 30658632 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal nutrient supplementation with iron and folic acid
Number of subjects: 601
Study 30658632 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre- and postnatal multiple micronutrients
Number of subjects: 601
Study 30658632 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements
Number of subjects: 601
Study 30658632 — intervention group
Group type: COMPARATOR
Intervention: Control group (aparasitaemic children)
Number of subjects: 601
Study 28062296 — intervention group
Group type: EXPERIMENTAL
Intervention: 40mg pravastatin for 1 year
Number of subjects: 79
Study 28062296 — intervention group
Group type: EXPERIMENTAL
Intervention: 40mg rosuvastatin
Number of subjects: 79
Study 28062296 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin after 8 weeks
Number of subjects: 79
Study 27035871 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 107
Study 27035871 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 107
Study 25091668 — intervention group
Group type: EXPERIMENTAL
Intervention: Withholding breastfeeding during the 30 min prior to and after each vaccine dose
Number of subjects: 400
Study 25091668 — intervention group
Group type: COMPARATOR
Intervention: Breastfeeding during the 30 min prior to and after each vaccine dose
Number of subjects: 400
Study 22815003 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol drip (0.2‐0.5 mg/kg bolus followed by continuous infusion of 212.5 ± 63.5 mg/h to 272.5 ± 89.5 mg/h over 24 hours)
Number of subjects: 10
Study 19639105 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% capsaicin
Number of subjects: 0
Study 19639105 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 0
Study 17156345 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined topical steroid (extra-fine inhaled beclomethasone 400 mcg/day and intranasal beclomethasone 200 mcg/day)
Number of subjects: 17
Study 17156345 — intervention group
Group type: COMPARATOR
Intervention: Combined mediator antagonism (montelukast 10 mg and cetirizine 10 mg)
Number of subjects: 17
Study 16037733 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane-fentanyl (group S)
Number of subjects: 120
Study 16037733 — intervention group
Group type: COMPARATOR
Intervention: Propofol-remifentanil (group T)
Number of subjects: 120
Study 11952053 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) sessions at -30 mm Hg for 1 hour per day from day 15 to day 21 of HDT.
Number of subjects: 12
Study 11952053 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LBNP sessions).
Number of subjects: 12
Study 11952053 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups during HDT.
Number of subjects: 12
Study 10612317 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (120 mg/d)
Number of subjects: 442
Study 10612317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 442
Study 7675241 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg/hr levodopa infusion
Number of subjects: 8
Study 7675241 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg/hr levodopa infusion
Number of subjects: 8
Study 7675241 — intervention group
Group type: COMPARATOR
Intervention: 0.0 mg/kg/hr levodopa infusion (placebo)
Number of subjects: 8
Study 2276391 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 100
Study 2276391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 7002059 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal antitetanus serum with steroid
Number of subjects: 107
Study 7002059 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 107
Study 7002059 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal antitetanus serum
Number of subjects: 107
Study 7002059 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal antitetanus serum (100 units or 50 units)
Number of subjects: 107
Study 7002059 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group
Number of subjects: 107
Study 31827347 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval training (INT) - alternating 3min at 90% HRpeak and 3min at 50% HRpeak for 12 sessions (60min each) over two weeks
Number of subjects: 22
Study 31827347 — intervention group
Group type: COMPARATOR
Intervention: Continuous training (CONT) - 70% HRpeak for 12 sessions (60min each) over two weeks
Number of subjects: 22
Study 27152427 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 160
Study 27152427 — intervention group
Group type: COMPARATOR
Intervention: Control (Normal Saline)
Number of subjects: 160
Study 26391630 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer educators intervention
Number of subjects: 2342
Study 26391630 — intervention group
Group type: COMPARATOR
Intervention: Control (no peer educators)
Number of subjects: 2342
Study 24565542 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination budesonide/formoterol as maintenance and reliever therapy
Number of subjects: 150
Study 24565542 — intervention group
Group type: COMPARATOR
Intervention: Combination budesonide/formoterol as maintenance treatment with albuterol as reliever
Number of subjects: 150
Study 21558771 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem use
Number of subjects: 0
Study 21558771 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-based hand sanitizer
Number of subjects: 0
Study 21558771 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem or meropenem
Number of subjects: 0
Study 18829212 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention for CPAP adherence, including audiotape with instructions and music, used nightly for 1 month.
Number of subjects: 97
Study 18829212 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group, no specific intervention details provided.
Number of subjects: 97
Study 17567342 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 400 microg
Number of subjects: 50
Study 17567342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15477125 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (100 microg every 6 h)
Number of subjects: 12
Study 15477125 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (12 microg every 12 h)
Number of subjects: 12
Study 11684081 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine
Number of subjects: 8
Study 11684081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 10396923 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular outpatient treatment (3 months)
Number of subjects: 0
Study 10396923 — intervention group
Group type: COMPARATOR
Intervention: Extended outpatient treatment (6 months)
Number of subjects: 0
Study 7993599 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealants applied with a drying agent
Number of subjects: 28
Study 7993599 — intervention group
Group type: COMPARATOR
Intervention: Sealants applied without a drying agent
Number of subjects: 28
Study 2525377 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free ipratropium bromide
Number of subjects: 33
Study 2525377 — intervention group
Group type: COMPARATOR
Intervention: Preservative-containing ipratropium bromide
Number of subjects: 33
Study 4881341 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous vasopressin injection (Pitressin)
Number of subjects: 50
Study 4881341 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study 31177180 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower glycated hemoglobin targets (6.5‐7.0%)
Number of subjects: 0
Study 31177180 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher glycated hemoglobin targets
Number of subjects: 0
Study 31177180 — intervention group
Group type: EXPERIMENTAL
Intervention: Modification of target levels based on clinical experience
Number of subjects: 0
Study 31177180 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose control over 5 years or more
Number of subjects: 0
Study 29637896 — intervention group
Group type: EXPERIMENTAL
Intervention: Mg lactate (MgLact2) supplementation
Number of subjects: 8
Study 29637896 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate (K3Citrate) for high UpH
Number of subjects: 8
Study 29637896 — intervention group
Group type: EXPERIMENTAL
Intervention: Ammonium chloride (NH4Cl) for low UpH
Number of subjects: 8
Study 29637896 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkali load (KCl)
Number of subjects: 8
Study 29637896 — intervention group
Group type: EXPERIMENTAL
Intervention: Mg supplementation
Number of subjects: 8
Study 29637896 — intervention group
Group type: COMPARATOR
Intervention: High UpH vs Low UpH
Number of subjects: 8
Study 25952160 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based behavioral intervention integrating motivational interviewing, active learning, and applied problem-solving.
Number of subjects: 136
Study 25952160 — intervention group
Group type: COMPARATOR
Intervention: Control condition with equivalent assessments and number of contacts without dietary advice.
Number of subjects: 136
Study 22134732 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 65
Study 22134732 — intervention group
Group type: COMPARATOR
Intervention: Antiresorptive agents combined with repeated PVPs
Number of subjects: 65
Study 21197525 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fluence, single-pass diode laser
Number of subjects: 22
Study 21197525 — intervention group
Group type: COMPARATOR
Intervention: Low-fluence, multiple-pass diode laser
Number of subjects: 22
Study 19920001 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization plus intensive medical therapy
Number of subjects: 2368
Study 19920001 — intervention group
Group type: COMPARATOR
Intervention: Intensive medical therapy alone
Number of subjects: 2368
Study 19920001 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin sensitization
Number of subjects: 2368
Study 19920001 — intervention group
Group type: COMPARATOR
Intervention: Insulin provision therapy
Number of subjects: 2368
Study 17023284 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile waveform transduced through an epidural needle
Number of subjects: 81
Study 17023284 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural catheters
Number of subjects: 81
Study 17023284 — intervention group
Group type: EXPERIMENTAL
Intervention: Group S‐P/Sims Portex catheters
Number of subjects: 81
Study 14632623 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Group
Number of subjects: 44
Study 14632623 — intervention group
Group type: COMPARATOR
Intervention: Non-pain Group
Number of subjects: 44
Study 10989990 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 32
Study 10989990 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 32
Study 9868028 — intervention group
Group type: EXPERIMENTAL
Intervention: Musical relaxation therapy
Number of subjects: 0
Study 9868028 — intervention group
Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 0
Study 8347328 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceranapril
Number of subjects: 0
Study 3646613 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered pain medication
Number of subjects: 64
Study 3646613 — intervention group
Group type: COMPARATOR
Intervention: Nurse-administered pain medication
Number of subjects: 64
Study 31480865 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-assisted technique (n=32)
Number of subjects: 64
Study 31480865 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique (n=32)
Number of subjects: 64
Study 31848443 — intervention group
Group type: EXPERIMENTAL
Intervention: Body-weight supported locomotor training (BWSLT)
Number of subjects: 37
Study 31848443 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 37
Study 29940151 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment arm (blood pressure target <= 120 mmHg)
Number of subjects: 9361
Study 29940151 — intervention group
Group type: COMPARATOR
Intervention: Control arm (blood pressure target <= 140 mmHg)
Number of subjects: 9361
Study 29940151 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse pressure increase (every 10 mmHg)
Number of subjects: 9361
Study 29940151 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined effect of pulse pressure and treatment intensity
Number of subjects: 9361
Study 29121884 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based physical activity intervention
Number of subjects: 152
Study 29121884 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 152
Study 25137430 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine continuous infusion at a rate of 0.4 μg kg(‐1) hour(‐1)
Number of subjects: 68
Study 25137430 — intervention group
Group type: COMPARATOR
Intervention: Physiologic saline infusion
Number of subjects: 68
Study 23393099 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally targeted patient navigation delivered by a professional navigator (Pro-PN)
Number of subjects: 315
Study 23393099 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally targeted patient navigation delivered by a community-based peer navigator (Peer-PN)
Number of subjects: 315
Study 21412761 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 1373
Study 21412761 — intervention group
Group type: COMPARATOR
Intervention: Non-users of SBRT
Number of subjects: 1373
Study 18241321 — intervention group
Group type: EXPERIMENTAL
Intervention: XR‐NTX 380 mg
Number of subjects: 624
Study 18241321 — intervention group
Group type: EXPERIMENTAL
Intervention: XR‐NTX 190 mg
Number of subjects: 624
Study 18241321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 624
Study 16796717 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse corticosteroid therapy
Number of subjects: 0
Study 16796717 — intervention group
Group type: COMPARATOR
Intervention: No protocol biopsies
Number of subjects: 0
Study 16796717 — intervention group
Group type: COMPARATOR
Intervention: Biopsies only in high-risk recipients
Number of subjects: 0
Study 16796717 — intervention group
Group type: COMPARATOR
Intervention: Universal screening protocol biopsy
Number of subjects: 0
Study 16796717 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased baseline immunosuppression
Number of subjects: 0
Study 16796717 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized clinical trial of biopsy and corticosteroid therapy
Number of subjects: 0
Study 14743949 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist (S) model
Number of subjects: 4
Study 14743949 — intervention group
Group type: EXPERIMENTAL
Intervention: Practitioner (P) model
Number of subjects: 4
Study 10693903 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychosocial support intervention
Number of subjects: 652
Study 9020413 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate 10 mg plus terbutaline 0.5 mg (group A)
Number of subjects: 62
Study 9020413 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus terbutaline 0.5 mg (group B)
Number of subjects: 62
Study 1413302 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin sulfate, 80 mg, administered 8-hourly for a total of three doses, starting just prior to the operation
Number of subjects: 110
Study 1413302 — intervention group
Group type: COMPARATOR
Intervention: Control group (no gentamicin prophylaxis)
Number of subjects: 110
Study 4042543 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.9 g/kg)
Number of subjects: 8
Study 4042543 — intervention group
Group type: COMPARATOR
Intervention: Placebo (400 ml of orange juice)
Number of subjects: 8
Study 31206016 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg) for 24 weeks
Number of subjects: 0
Study 31206016 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg) for 24 weeks
Number of subjects: 0
Study 31206016 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 24 weeks
Number of subjects: 0
Study 31206016 — intervention group
Group type: COMPARATOR
Intervention: Matched controls (not specified)
Number of subjects: 0
Study 29237386 — intervention group
Group type: EXPERIMENTAL
Intervention: ω‐3 fatty acids
Number of subjects: 72
Study 29237386 — intervention group
Group type: EXPERIMENTAL
Intervention: nano‐curcumin
Number of subjects: 72
Study 29237386 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ω‐3 fatty acids and nano‐curcumin
Number of subjects: 72
Study 29237386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 26871968 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth potassium citrate (220 mg), esomeprazole (20 mg), amoxicillin (1.0 g), and furazolidone (100 mg) twice daily for 14 days with left lateral horizontal position for 30 min after dosing (GS group 1)
Number of subjects: 126
Study 26871968 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth potassium citrate (220 mg), esomeprazole (20 mg), amoxicillin (1.0 g), and furazolidone (100 mg) twice daily for 14 days (GS group 2)
Number of subjects: 126
Study 26871968 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-gastrectomized patients)
Number of subjects: 126
Study 26871968 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including GS group 1 and GS group 2)
Number of subjects: 126
Study 26871968 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 126
Study 25521726 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg/day
Number of subjects: 66
Study 25521726 — intervention group
Group type: COMPARATOR
Intervention: Teprenone 150 mg/day
Number of subjects: 66
Study 22354457 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGB)
Number of subjects: 23
Study 22354457 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 23
Study 22354457 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 23
Study 20849620 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 or 16 fluid ounces of vegetable juice daily
Number of subjects: 0
Study 20849620 — intervention group
Group type: COMPARATOR
Intervention: 0 fluid ounces of vegetable juice daily (Control)
Number of subjects: 0
Study 17761704 — intervention group
Group type: EXPERIMENTAL
Intervention: EC (epirubicin/cyclophosphamid)
Number of subjects: 58
Study 17761704 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose intensified E (epirubicin) followed by taxane
Number of subjects: 58
Study 17761704 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF (cyclophosphamid/methorexate/fluorouracil)
Number of subjects: 58
Study 17761704 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial response of CETC
Number of subjects: 58
Study 15755847 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine treatment (n = 99; initial dose 8 microg/kg)
Number of subjects: 196
Study 15755847 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 97)
Number of subjects: 196
Study 16515992 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive family history screening
Number of subjects: 1364
Study 16515992 — intervention group
Group type: COMPARATOR
Intervention: Sporadic cases screening
Number of subjects: 1364
Study 16515992 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall biochemical-free survival rate
Number of subjects: 1364
Study 10665102 — intervention group
Group type: EXPERIMENTAL
Intervention: Public health efforts to prompt cessation in half the communities
Number of subjects: 1410
Study 8880018 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 620
Study 8880018 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 620
Study 2012585 — intervention group
Group type: EXPERIMENTAL
Intervention: Creative novation behaviour therapy (long-term individual therapy, group therapy, bibliotherapy plus short-term individual treatment)
Number of subjects: 0
Study 2012585 — intervention group
Group type: COMPARATOR
Intervention: Psychoanalysis
Number of subjects: 0
Study 6665837 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole (40 mg/kg body-weight in one daily dose for five days)
Number of subjects: 0
Study 6665837 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole plus diloxanide furoate (tinidazole at 40 mg/kg body-weight in one daily dose for five days and diloxanide furoate at 20 mg/kg body-weight divided into three daily doses for 10 days)
Number of subjects: 0
Study 31486981 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapy
Number of subjects: 0
Study 31486981 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30051499 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.75 mg/d
Number of subjects: 459
Study 30051499 — intervention group
Group type: COMPARATOR
Intervention: Control (no extra treatment)
Number of subjects: 459
Study 26018749 — intervention group
Group type: EXPERIMENTAL
Intervention: ACLS training module: Laerdal® ALS Skillmaster
Number of subjects: 30
Study 25033789 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC) 1200 mg/day
Number of subjects: 48
Study 25033789 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginseng 200 mg/day
Number of subjects: 48
Study 25033789 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplement)
Number of subjects: 48
Study 22441301 — intervention group
Group type: EXPERIMENTAL
Intervention: aranidipine 5-10 mg/d (n = 118)
Number of subjects: 236
Study 22441301 — intervention group
Group type: COMPARATOR
Intervention: amlodipine 5-10 mg/d (n = 118)
Number of subjects: 236
Study 20122576 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic treatment with statins for at least 6 months (group B)
Number of subjects: 103
Study 20122576 — intervention group
Group type: COMPARATOR
Intervention: No treatment with statins (group A)
Number of subjects: 103